Cart
sales@molnova.com
ST-193
CAS No. 489416-12-8
ST-193( ST193 | ST 193 )
Catalog No. M14643 CAS No. 489416-12-8
ST-193 (ST193) is a potent, selective, broad-spectrum arenavirus entry inhibitor with IC50 of 1.6 nM against LASV pseudotypes, targets arenavirus envelope glycoprotein.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 215 | Get Quote |
|
| 10MG | 368 | Get Quote |
|
| 25MG | 614 | Get Quote |
|
| 50MG | 872 | Get Quote |
|
| 100MG | 1161 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameST-193
-
NoteResearch use only, not for human use.
-
Brief DescriptionST-193 (ST193) is a potent, selective, broad-spectrum arenavirus entry inhibitor with IC50 of 1.6 nM against LASV pseudotypes, targets arenavirus envelope glycoprotein.
-
DescriptionST-193 (ST193) is a potent, selective, broad-spectrum arenavirus entry inhibitor with IC50 of 1.6 nM against LASV pseudotypes, targets arenavirus envelope glycoprotein; Also inhibits pseudotypes generated with other arenavirus envelopes with IC50 of 0.2-12 nM, but exhibited no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus LCMV or the unrelated G protein from vesicular stomatitis virus (IC50>10 uM); exhibits antiviral activity against Lassa virus (LASV) in a guinea pig model (i.p.).
-
In VitroST-193 inhibits LASV pseudotypes with an IC50 of 1.6 nM. ST-193 inhibits pseudotypes generated with other arenavirus envelopes as well, including the remaining four commonly associated with hemorrhagic fever (IC50s for Junín, Machupo, Guanarito, and Sabiá were in the 0.2 to 12 nM range) but exhibits no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus lymphocytic choriomeningitis virus or the unrelated G protein from vesicular stomatitis virus, at concentrations of up to 10 μM.
-
In VivoST-193 is found to be tolerated well when administered daily as an intraperitoneal injection of either 25 or 100 mg/kg/day for 14 days. ST-193-treated animals exhibit fewer signs of disease and enhance survival when compared to the ribavirin or vehicle groups. Body temperatures in all groups are elevated by day 9, but returned to normal by day 19 postinfection in the majority of ST-193-treated animals. ST-193 treatment mediates a 2- to 3-log reduction in viremia relative to vehicle-treated controls. The overall survival rate for the ST-193-treated guinea pigs is 62.5% (10/16) compared with 0% in the ribavirin (0/8) and vehicle (0/7) groups.
-
SynonymsST193 | ST 193
-
PathwayMicrobiology/Virology
-
TargetArenavirus
-
RecptorArenavirus
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number489416-12-8
-
Formula Weight371.4748
-
Molecular FormulaC24H25N3O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 150 mg/mL
-
SMILESCC(C)C1=CC=C(C=C1)CNC2=CC3=C(C=C2)N(C=N3)C4=CC=C(C=C4)OC
-
Chemical Name1H-Benzimidazol-5-amine, 1-(4-methoxyphenyl)-N-[[4-(1-methylethyl)phenyl]methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Larson RA, et al. J Virol. 2008 Nov;82(21):10768-75.
2. York J, et al. J Virol. 2008 Nov;82(21):10932-9.
3. Cashman KA, et al. Antiviral Res. 2011 Apr;90(1):70-9.
4. Dai D, et al. Bioorg Med Chem Lett. 2013 Feb 1;23(3):744-9.
molnova catalog
related products
-
Nucleoprotein 396-40...
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen.
-
LCMV gp33-41
LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.This is the H-2Db restricted epitope derived from the lymphocytic choreomeningitis virus (LCMV) glycoprotein gp 33; residues 33 to 41.
-
LASV inhibitor 3.3
LASV inhibitor 3.3 (LAMP1 inhibitor 3.3) is a specific inhibitor of Lassa fever virus (LASV, IC50=1.8 uM).
